NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies
- 189 Downloads
3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-d-glucose (FDG).
Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [18F]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (K FLT), blood to tissue transport (K 1), and phosphorylation (k 3). FDG-PET scans were obtained 75–90 min postinjection.
K FLT and k 3, but not K 1 or k 3/k 2 + k 3, reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance.
K FLT (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.
Key Words3′-[18F]fluoro-3′-deoxythymidine FLT Fluorothymidine Positron emission tomography (PET) Glioma Radionecrosis Proliferation imaging
Pam Pham, Michele F. Wanner, Jeffrey Scharnhorst, and Neha Patel are gratefully acknowledged for their indispensable help. Supported by National Cancer Institute Contract N01-CM-37008 and NIH grants CA42045 and S10 RR17229.
- 33.Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE (2006) 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 8:340–347PubMedCrossRefGoogle Scholar